ARTBIO’s Post

We’re thrilled to announce a collaboration with the world-class team at ARTBIO that expands our pipeline of cancer therapies into #radiopharmaceuticals, a class of drugs we believe will make an extraordinary impact on patient outcomes. Along with ARTBIO we will be co-creating and co-commercializing Helicon-enabled alpha-particle radioligand therapies, drawing on the unique strengths of each of our platforms to produce a new category of targeted radioligand therapy. We believe the combination could produce the best radiopharmaceutical platform that exists in our industry today: On the one side, ARTBIO is uniquely able to accomplish distributed manufacturing of lead-212 (²¹²Pb), one of the most promising isotopes for radiopharmaceutical use but that is challenging to utilize because of its short half-life. On the other side, Fog’s Helicon platform could be a best-in-class carrier of radiopharmaceuticals because of our ability to precisely tune our peptides to control tissue distribution and half-life. The general hyper-tunability of Helicons opens new possibilities both for intracellular targeting — where Fog’s wholly-owned pipeline is focused — as well as for extracellular delivery. At the intersection of these two unmatched platforms, there’s huge potential to create therapies that improve, extend and save the lives of people with cancer. Learn more in our press release: https://bwnews.pr/3wBXF7L #radioligandtherapy #cancer #oncology #peptides #Helicons #radiopharmaceutical #patients

Close to 200 Liquid biopsy trials in oncology are registered between 2021-2022. This area is growing by leaps and bounds. From disease monitoring to therapy guidance liquid biopsy is the future of cancer treatment. Importantly, a cancer drug which is developed in parallel with a CDx assay (companion diagnostic or liquid biopsy assay in this context) can reduce drug development cost by 60%- not to mention that cancer drug development cost could be as high as >$1B. Therefore, liquid biopsy has huge impact on cost reduction in drug development process. Surprisingly, data shows that a new cancer drug application filed to FDA see as high as 30% approval rate as oppose to 8-10% when without CDx assay. The impact of liquid biopsy technologies in patient care as well as in drug development process is far from realized yet and could make a tectonic shift in oncology research in coming years. #oncology #pharma #liquidbiopsy #cancer #immunooncology #biotech https://lnkd.in/dKf-h4ac.

HCB101, an engineered extracellular domain of SIRPα fused to the Fc region of IgG4 as the foundation of the innate immunity checkpoint #immunotherapy , is HanchorBio Inc. 漢康生技股份有限公司 first candidate. We’re deeply grateful to our first patient, investigators/researchers, this clinical sites in US and Taiwan, our CRO, vendors, and consultants whose participation and dedication have played a critical role in advancing our Phase 1 study (NCT05892718). The initiation of this study of HCB101 is an important achievement that brings us closer to delivering a potential new treatment which may have a life-changing impact for #cancer patients who do not respond to currently available #treatment options and can result in death. #biotechnology #oncology #medicine https://lnkd.in/e4yTdhN6

eFFECTOR Therapeutics, Inc. said it will halt development of tomivosertib in #lungcancer after the MNK inhibitor failed to significantly improve survival. https://lnkd.in/d3cMqd4y #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #oncology #pharmaceuticals

TWENTY-FIVE YEARS WITH HER2 TARGETED THERAPY On September 25, 1998, the FDA approved the monoclonal antibody trastuzumab (Herceptin) and the immunohistochemical assay HercepTest for the treatment of patients with HER2-positive metastatic breast cancer. Trastuzumab is among the most significant cancer drug development projects in the 20th century, and the drug became a "game-changer" for the treatment of HER2-positive breast cancer resulting in a reduction in cancer recurrence and improvement of survival. The development of trastuzumab was the beginning of a new era in cancer drug development. The drug-diagnostic co-development model, in which a drug is developed in parallel with a predictive biomarker assay, has significantly impacted the current development of cancer drugs. The Danish Society for Cyto- and Histochemistry wishes to celebrate this event with a scientific meeting held on September 21, 2023, at Herlev Hospital, Copenhagen. It is FREE to participate but registration is required on https://lnkd.in/ekRNHWGm no later than September 15, 2023. #oncology #healthcare #pharmaceutical #precisionmedicine #personalizedmedicine

Race Oncology today released a new corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential. Our new strategy is structured to maximise the inherent value of bisantrene as follows: · Anti-cancer cardio-protection. Our core focus is to deliver an impact on cancer and the challenges of chemotherapeutic #cardiotoxicity. Our clinical program will leverage the unique mechanisms of bisantrene in metastatic breast cancer (mBC) and acute myeloid leukaemia (AML), both cancer patient populations with high unmet need. · Discovery. Our discovery program is designed to further elucidate both cardio-protective mechanisms of action and the findings by City of Hope that bisantrene is the most potent inhibitor of FTO. · New bisantrene. Our new bisantrene program is designed to strengthen intellectual property for bisantrene and to develop the next generation of bisantrene. Race has committed and planned programs informed by international key opinion leaders with global development experience, to best leverage the significant opportunity offered by bisantrene as an anti-cancer and cardio-protective agent, while also investigating its potential as an inhibitor of the FTO pathway. Our clinical program enhances and delivers a unique commercial opportunity that can be realised by the appropriate in-market pharmaceutical company. Read the full strategic update here: https://lnkd.in/ggdZezgD #bisantrene #oncology #bisantrene #RAC #AML #mBC #cardioprotection #breastcancer

The combination of Johnson & Johnson's bispecific antibody #Rybrevant (amivantamab-vmjw) and #Leclaza (lazertinib), a third-generation EGFR tyrosine kinase inhibitor, significantly improved progression-free survival (PFS) by 30% compared to AstraZeneca's #Tagrisso (osimertinib) in first-line patients with locally advanced or metastatic EGFR-mutated non-small-cell #lungcancer (NSCLC). https://lnkd.in/gSJUXqCj #AstraZeneca #cancer #clinicalresearch #clinicaltrials #ESMO #JnJ #medicalaffairs #NSCLC #oncology #pharmaceuticals

🔬 Alentis Therapeutics: First patient dosed in HNCC clinical trial The first patient has been dosed in the Phase 1/2 clinical trial of ALE.C04 for head and neck squamous cell carcinoma (HNCC). Led by Anthony El-khoueiry, MD, at the USC Norris Comprehensive Cancer Center, the trial (NCT06054477) will assess ALE.C04's safety, tolerability, and efficacy in 220 adults with recurrent or metastatic #HNCC. The study includes both monotherapy and combination therapy with pembrolizumab. Alentis, a clinical-stage biotech focusing on Claudin-1 (CLDN1) positive tumors, is pioneering anti-CLDN1 antibodies to modify and reverse disease progression. 👉 Read More: https://lnkd.in/gDCeHwmr #HealthcareInnovation #AccelerateInBasel #therapeutics #biotech #cancerresearch